세계의 어류 백신 시장

Global Fish Vaccines Market to Reach US$577.5 Million by 2030

The global market for Fish Vaccines estimated at US$363.9 Million in the year 2024, is expected to reach US$577.5 Million by 2030, growing at a CAGR of 8.0% over the analysis period 2024-2030. Killed Vaccine, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$183.0 Million by the end of the analysis period. Growth in the Inactivated Vaccine segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$99.1 Million While China is Forecast to Grow at 12.9% CAGR

The Fish Vaccines market in the U.S. is estimated at US$99.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$126.5 Million by the year 2030 trailing a CAGR of 12.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.

Global Fish Vaccines Market - Key Trends & Drivers Summarized

Why Are Fish Vaccines Becoming Critical to Sustainable Aquaculture Growth?

Fish vaccines have emerged as a cornerstone of sustainable aquaculture practices, offering a proactive and scientifically advanced method for controlling infectious diseases in farmed fish populations. As aquaculture continues to outpace wild-capture fisheries in supplying global seafood demand, disease outbreaks have become one of the most significant threats to productivity, profitability, and biosecurity. Vaccination provides an environmentally responsible alternative to antibiotics, aligning with global initiatives to combat antimicrobial resistance (AMR) and reduce chemical use in food production. Fish vaccines are commonly deployed against bacterial, viral, and parasitic pathogens such as Aeromonas salmonicida, Vibrio anguillarum, and infectious pancreatic necrosis virus (IPNV), among others. These diseases, if unmanaged, can lead to high mortality rates, compromised fish health, and severe economic losses. Governments and industry stakeholders are increasingly mandating or incentivizing vaccination as a standard best practice, particularly in high-value species like salmon, tilapia, seabass, and trout. As a result, fish vaccines are no longer considered optional in intensive aquaculture-they are now essential for maintaining herd immunity, production efficiency, and global seafood supply chain stability.

How Are Technological Advancements Expanding the Reach and Efficacy of Fish Vaccines?

Technological innovations in vaccine formulation, delivery, and diagnostic support are significantly enhancing the effectiveness and accessibility of fish vaccines. Traditional inactivated and live-attenuated vaccines are now being supplemented by recombinant, subunit, and DNA vaccines that offer greater specificity, longer immunity, and reduced risk of side effects. Encapsulation and adjuvant technologies are improving vaccine uptake and immunogenicity, even in challenging aquatic environments. Innovations in oral and immersion-based delivery methods are making vaccination more practical and less stressful for fish populations compared to conventional injection-based approaches, particularly in small or juvenile fish. At the same time, precision farming tools-such as real-time water quality monitoring and disease surveillance systems-are enabling targeted vaccination schedules and better outbreak prevention. The use of genomics and molecular diagnostics is also helping identify emerging pathogens and develop species-specific vaccines at a faster rate. Automated vaccine administration systems, particularly in high-volume fish farms, are improving labor efficiency and ensuring consistent dosing. These technological advancements are not only improving the scalability of fish vaccination programs but are also enabling broader adoption in developing aquaculture sectors where manual labor and infrastructure are limited.

What Role Do Regulations, Biosecurity Demands, and Industry Collaboration Play in Market Expansion?

Regulatory support and coordinated industry efforts are playing a central role in scaling up the fish vaccines market globally. In countries with advanced aquaculture industries-such as Norway, Chile, Scotland, and Canada-government policies and veterinary authorities actively promote vaccine use as part of national fish health management frameworks. Vaccination is often required for certification, export approval, and participation in disease-free zone programs. Biosecurity regulations that restrict the use of antibiotics and chemicals are further reinforcing the adoption of vaccines as a core disease mitigation strategy. In emerging markets across Asia-Pacific, Africa, and Latin America, public-private partnerships and donor-funded aquaculture development programs are helping build the infrastructure and training needed to implement vaccination at scale. Regional aquaculture associations and research institutions are also collaborating with pharmaceutical companies to develop localized vaccine strains that address specific pathogen challenges in tropical and subtropical climates. Additionally, traceability and sustainability certifications-such as those offered by the Aquaculture Stewardship Council (ASC)-increasingly reward farms that integrate vaccines into health management plans, boosting market access and consumer trust. These collaborative and regulatory dynamics are aligning economic incentives, public health objectives, and industry growth with a shared commitment to responsible aquaculture.

What’s Driving the Global Surge in Demand for Fish Vaccines?

The growth in the global fish vaccines market is driven by a combination of rising aquaculture output, intensifying disease pressures, regulatory shifts, and sustainability imperatives. A key driver is the ongoing expansion of aquaculture as a primary protein source, particularly in countries like China, India, Indonesia, and Vietnam, where fish farming is central to food security and rural livelihoods. As production becomes more intensive, the risk of disease transmission within and between farms escalates, necessitating comprehensive vaccination strategies. Increasing consumer demand for antibiotic-free seafood-particularly in Europe and North America-is also pushing producers to adopt vaccines as a market-access requirement. Technological innovations are enabling cost-effective vaccine production, multi-pathogen formulations, and improved logistics, making fish vaccines viable even for small- and medium-scale producers. Meanwhile, climate change and environmental degradation are altering pathogen dynamics and increasing the frequency of stress-induced disease outbreaks, further highlighting the need for preventative fish health solutions. Continued investment from animal health companies, aquaculture biotech firms, and government agencies is accelerating vaccine research, strain libraries, and global distribution networks. These growth drivers-spanning biological necessity, market demand, regulatory policy, and environmental stewardship-are collectively powering the global fish vaccines market into a phase of rapid expansion and strategic importance for the future of sustainable aquaculture.

SCOPE OF STUDY:

The report analyzes the Fish Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine, Recombinant Vector Vaccines); Indication (Furunculosis, Vibriosis, Yersiniosis, Enteric Septicemia, Other Indications); Administration Route (Injection, Immersion, Spray, Oral)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AquaTactics Fish Health
• Benchmark Holdings plc
• CAVAC
• Ceva Sante Animale
• Chengdu Tech-bank Biological Products
• Elanco Animal Health Inc.
• HIPRA
• Indian Immunologicals Ltd.
• KBNP Inc.
• Kemin Industries
• Kyoritsuseiyaku Corporation
• Kyoto Biken Laboratories, Inc.
• Merck Animal Health
• Nisseiken Co., Ltd.
• Phibro Animal Health Corporation
• Tecnovax
• Vaxxinova International BV
• Veterquimica S.A.
• Virbac
• Zoetis Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Fish Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Disease Prevention in Aquaculture Propels Growth in the Fish Vaccines Market
  • Expansion of Commercial Fish Farming Operations Expands the Addressable Market for Preventive Veterinary Vaccines
  • Increased Incidence of Bacterial, Viral, and Parasitic Outbreaks Throws the Spotlight on Fish Health Management
  • Regulatory Push for Antibiotic-Free Aquaculture Strengthens the Business Case for Vaccination-Based Disease Control
  • Technological Advancements in Oral, Immersion, and DNA Vaccines Drive Innovation in Fish Immunization Methods
  • Growth in Global Seafood Consumption Supports Long-Term Investment in Sustainable Fish Health Solutions
  • Rising Awareness of Economic Losses Due to Fish Mortality and Morbidity Spurs Demand for Effective Vaccines
  • Integration of Fish Vaccines in Hatchery Management and Early Life Stage Programs Improves Survival Rates and ROI
  • Emerging Zoonotic and Cross-Species Pathogen Risks Throw the Spotlight on Proactive Aquatic Disease Prevention
  • Customization of Vaccines for Species-Specific and Region-Specific Pathogens Enhances Market Precision and Impact
  • Growth in Recirculating Aquaculture Systems (RAS) Drives Need for Controlled, Preventive Fish Health Strategies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Fish Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Fish Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Fish Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Fish Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Killed Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Killed Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Killed Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Inactivated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Attenuated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Toxoid Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Toxoid Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Toxoid Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Subunit Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Conjugate Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Recombinant Vector Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Recombinant Vector Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Recombinant Vector Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Yersiniosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Yersiniosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Yersiniosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Enteric Septicemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Enteric Septicemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Enteric Septicemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Furunculosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Furunculosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Furunculosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Vibriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Vibriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Vibriosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Immersion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Immersion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Immersion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Spray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Spray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Spray by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• JAPAN
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• CHINA
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 80: China Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• EUROPE
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Fish Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Fish Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Fish Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• FRANCE
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 101: France Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• GERMANY
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 128: UK Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 134: UK Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: UK Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: UK 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 143: Spain Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Spain Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Spain 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 152: Russia Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Russia Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Russia 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Europe Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Rest of Europe 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Fish Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Fish Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Asia-Pacific Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Asia-Pacific 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 182: Australia Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Australia Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Australia 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• INDIA
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 185: India Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 191: India Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: India Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: India 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 200: South Korea Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: South Korea Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: South Korea 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Asia-Pacific Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Fish Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Fish Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 221: Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Latin America Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Latin America 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 230: Argentina Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Argentina Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Argentina 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 239: Brazil Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Brazil Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Brazil 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 248: Mexico Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Mexico Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Mexico 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Latin America Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Latin America 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Fish Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Fish Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 269: Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Middle East Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Middle East 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 278: Iran Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Iran Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Iran 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 287: Israel Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Israel Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Israel 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Saudi Arabia Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Saudi Arabia 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 305: UAE Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: UAE Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: UAE 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Middle East Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Middle East 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• AFRICA
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 323: Africa Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Africa Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Africa 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030

IV. COMPETITION